Net earnings per share (EPS TTM): Revance Therapeutics, Inc (RVNC)

Symbol and logo of brand Revance Therapeutics (RVNC)

The 12-month net income per share history illustrates the dynamics of Revance Therapeutics (RVNC), where -1.94 is the current value of the metric. Revance Therapeutics is resisting aggressive pressure from global aesthetics behemoths. Long-acting neurotoxins ensure stable demand and build customer loyalty. Meanwhile, management is mitigating production outsourcing risks through strict technical control of external sites.

RVNC Revance Therapeutics Earnings per share for the last 12 months (07/04/2022 - 02/16/2025)

Analytical breakdowns and data insights for company Revance Therapeutics (RVNC)

- current quotes and average value forecast:
- company stock exchange capitalization indicators:
Fundamental company valuation:revance.com (RVNC)
Manufactured products of Revance Therapeutics Inc

For Revance Therapeutics (RVNC), which monetizes the premium status of its Daxxify drug, earnings per share serve as the benchmark for the efficiency of capitalizing on its technological advantage. This metric is calculated by dividing the total annual net income by the total number of outstanding shares. The net income per share trend over the last 12 months (TTM) reflects the business's actual ability to generate value. The growth of this indicator confirms the success of its high-pricing strategy. Investors should view this trend as confirmation of the business model's sustainability.